TY - JOUR
T1 - Polyunsaturated fatty acids and risk of Alzheimer’s disease
T2 - a Mendelian randomization study
AU - Tomata, Yasutake
AU - Larsson, Susanna C.
AU - Hägg, Sara
N1 - Funding Information:
Open access funding provided by Karolinska Institute. We would like to thank Juulia Jylh?v?, Xiaoying Kang, Yunzhang Wang, and Ichiro Tsuji for their technical assistance. This work was supported by the Swedish Council for Working Life and Social Research (FORTE) (2013-2292), the Swedish Research Council (2015-03255), and Leading Young Researcher Overseas Visit Program from Tohoku University, Japan.
Funding Information:
Open access funding provided by Karolinska Institute. We would like to thank Juulia Jylhävä, Xiaoying Kang, Yunzhang Wang, and Ichiro Tsuji for their technical assistance. This work was supported by the Swedish Council for Working Life and Social Research (FORTE) (2013-2292), the Swedish Research Council (2015-03255), and Leading Young Researcher Overseas Visit Program from Tohoku University, Japan.
Publisher Copyright:
© 2019, The Author(s).
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Purpose: Observational studies have suggested that polyunsaturated fatty acids (PUFAs) may decrease Alzheimer’s disease (AD) risk. In the present study, we examined this hypothesis using a Mendelian randomization analysis. Methods: We used summary statistics data for single-nucleotide polymorphisms associated with plasma levels of n-6 PUFAs (linoleic acid, arachidonic acid) and n-3 PUFAs (alpha-linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid), and the corresponding data for AD from a genome-wide association meta-analysis of 63,926 individuals (21,982 diagnosed AD cases, 41,944 controls). Results: None of the genetically predicted PUFAs was significantly associated with AD risk; odds ratios (95% confidence interval) per 1 SD increase in PUFA levels were 0.98 (0.93, 1.03) for linoleic acid, 1.01 (0.98, 1.05) for arachidonic acid, 0.96 (0.88, 1.06) for alpha-linolenic acid, 1.03 (0.93, 1.13) for eicosapentaenoic acid, 1.03 (0.97, 1.09) for docosapentaenoic acid, and 1.01 (0.81, 1.25) for docosahexaenoic acid. Conclusions: This study did not support the hypothesis that PUFAs decrease AD risk.
AB - Purpose: Observational studies have suggested that polyunsaturated fatty acids (PUFAs) may decrease Alzheimer’s disease (AD) risk. In the present study, we examined this hypothesis using a Mendelian randomization analysis. Methods: We used summary statistics data for single-nucleotide polymorphisms associated with plasma levels of n-6 PUFAs (linoleic acid, arachidonic acid) and n-3 PUFAs (alpha-linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid), and the corresponding data for AD from a genome-wide association meta-analysis of 63,926 individuals (21,982 diagnosed AD cases, 41,944 controls). Results: None of the genetically predicted PUFAs was significantly associated with AD risk; odds ratios (95% confidence interval) per 1 SD increase in PUFA levels were 0.98 (0.93, 1.03) for linoleic acid, 1.01 (0.98, 1.05) for arachidonic acid, 0.96 (0.88, 1.06) for alpha-linolenic acid, 1.03 (0.93, 1.13) for eicosapentaenoic acid, 1.03 (0.97, 1.09) for docosapentaenoic acid, and 1.01 (0.81, 1.25) for docosahexaenoic acid. Conclusions: This study did not support the hypothesis that PUFAs decrease AD risk.
KW - Alzheimer’s disease
KW - Mendelian randomization analysis
KW - Polyunsaturated fatty acids
UR - http://www.scopus.com/inward/record.url?scp=85074732391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074732391&partnerID=8YFLogxK
U2 - 10.1007/s00394-019-02126-x
DO - 10.1007/s00394-019-02126-x
M3 - Article
C2 - 31676950
AN - SCOPUS:85074732391
SN - 1436-6207
VL - 59
SP - 1763
EP - 1766
JO - Zeitschrift fur Ernahrungswissenschaft
JF - Zeitschrift fur Ernahrungswissenschaft
IS - 4
ER -